. Author manuscript; available in PMC: 2015 Jan 7.

Published in final edited form as: Clin Colorectal Cancer. 2011 Jul 22;10(4):310–316. doi: 10.1016/j.clcc.2011.06.005

Table 3.

Number of Patients With a Given Type and Grade of Adverse Event^a

	Calcium Carbonate							Placebo
	(n = 95)							(n = 99)
	Grade							Grade
Adverse Event	Unk	0	1	2	3	4	5	Unk	0	1	2	3	4	5
Allergy/hypersensitivity	0	98	0	1	0	0	0	0	101	0	0	0	0	0
Bilirubin increase	0	94	4	0	1	0	0	0	92	8	1	0	0	0
Constipation/bowel obstruction	0	80	14	4	1	0	0	0	83	11	7	0	0	0
Creatinine increase	0	96	3	0	0	0	0	0	95	5	1	0	0	0
Diarrhea without colostomy	1	95	1	1	1	0	0	0	100	0	0	1	0	0
Dyspnea	0	98	0	1	0	0	0	0	101	0	0	0	0	0
Hypercalcemia	0	97	1	0	0	1	0	0	99	2	0	0	0	0
Nausea	1	96	1	1	0	0	0	0	99	1	1	0	0	0
Proteinuria	0	99	0	0	0	0	0	0	100	0	1	0	0	0
SGOT (AST) increase	0	99	0	0	0	0	0	0	100	0	1	0	0	0
SGPT (ALT) increase	0	99	0	0	0	0	0	0	100	0	1	0	0	0
Weight gain	0	98	0	1	0	0	0	0	101	0	0	0	0	0
Maximum Grade Any Adverse Event (N)	2	65	20	8	3	1	0	0	61	29	10	1	0	0

Adverse events unlikely or not related to treatment excluded adverse events with no entries for grades 2 to 5 have been suppressed.